TSHA vs. ANIP, DYN, INDV, AMPH, ARDX, EVO, ETNB, OCUL, GPCR, and IOVA
Should you be buying Taysha Gene Therapies stock or one of its competitors? The main competitors of Taysha Gene Therapies include ANI Pharmaceuticals (ANIP), Dyne Therapeutics (DYN), Indivior (INDV), Amphastar Pharmaceuticals (AMPH), Ardelyx (ARDX), Evotec (EVO), 89bio (ETNB), Ocular Therapeutix (OCUL), Structure Therapeutics (GPCR), and Iovance Biotherapeutics (IOVA). These companies are all part of the "pharmaceutical products" industry.
Taysha Gene Therapies vs.
Taysha Gene Therapies (NASDAQ:TSHA) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, valuation, earnings, community ranking, risk and analyst recommendations.
ANI Pharmaceuticals received 332 more outperform votes than Taysha Gene Therapies when rated by MarketBeat users. However, 77.54% of users gave Taysha Gene Therapies an outperform vote while only 64.46% of users gave ANI Pharmaceuticals an outperform vote.
77.7% of Taysha Gene Therapies shares are held by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are held by institutional investors. 2.7% of Taysha Gene Therapies shares are held by company insiders. Comparatively, 12.7% of ANI Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Taysha Gene Therapies presently has a consensus target price of $6.63, suggesting a potential upside of 292.24%. ANI Pharmaceuticals has a consensus target price of $79.75, suggesting a potential upside of 19.96%. Given Taysha Gene Therapies' higher possible upside, analysts clearly believe Taysha Gene Therapies is more favorable than ANI Pharmaceuticals.
ANI Pharmaceuticals has higher revenue and earnings than Taysha Gene Therapies. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Taysha Gene Therapies, indicating that it is currently the more affordable of the two stocks.
ANI Pharmaceuticals has a net margin of -1.28% compared to Taysha Gene Therapies' net margin of -229.67%. ANI Pharmaceuticals' return on equity of 15.87% beat Taysha Gene Therapies' return on equity.
Taysha Gene Therapies has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500. Comparatively, ANI Pharmaceuticals has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500.
In the previous week, ANI Pharmaceuticals had 9 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 10 mentions for ANI Pharmaceuticals and 1 mentions for Taysha Gene Therapies. Taysha Gene Therapies' average media sentiment score of 1.32 beat ANI Pharmaceuticals' score of 0.68 indicating that Taysha Gene Therapies is being referred to more favorably in the media.
Summary
Taysha Gene Therapies and ANI Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks.
Get Taysha Gene Therapies News Delivered to You Automatically
Sign up to receive the latest news and ratings for TSHA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Taysha Gene Therapies Competitors List
Related Companies and Tools
This page (NASDAQ:TSHA) was last updated on 3/25/2025 by MarketBeat.com Staff
Buy TSHA Stock Free TSHA Stock Alerts